Doing now what patients need next
:quality(90)/)
We are Roche
A healthier future. It’s what drives us to innovate.
To continuously advance science and ensure everyone has access to the healthcare they need today and for generations to come.
Creating a world where we all have more time with the people we love.
That’s what makes us Roche.
In the spotlight
:quality(90)/)
:quality(90)/)
For Investors
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
We will prevent diseases by identifying high-risk patients early to enable timely use of medicines.
:quality(90)/)
We will stop diseases by accurately diagnosing and stratifying patients to halt disease progression through targeted medicines.
:quality(90)/)
We will cure diseases by identifying the cause of disease in order to restore health through curative medicines.
:quality(90)/)
:quality(90)/)
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
Basel, 18 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, early-stage breast cancer.
:quality(90)/)
Roche Accessibility Statement
At Roche, we are committed to ensuring that our websites and digital resources are accessible to all users.
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)